BioSpace News Archive

Exelixis, Inc. (NASDAQ:EXEL) today announced a collaboration agreement with Roche to evaluate cabozantinib (CABOMETYX®), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, in combination with atezolizumab (TECENTRIQ®), Roche’s PD-L1 immune checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

Helius Medical Technologies, Inc. announced that the results from independent research conducted at the University of Wisconsin-Madison on translingual neurostimulation for the treatment of chronic symptoms due to mild-to moderate traumatic brain injury have been published in the December 2019 issue of the Archives of Rehabilitation Research and Clinical Translation.

Annamycin shows unusually high lung uptake and anticancer activity against lung metastases of multiple solid tumors

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 11:30 a.m.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the company will present at the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the successful closing of the research collaboration and licensing agreement between Dicerna and Roche following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

Salarius Pharmaceuticals, Inc. announced that its chief executive officer, David Arthur, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

Plinabulin Protects Bone Marrow from Chemotherapy-Induced Deficiencies with a Differentiated Yet Complimentary Mechanism to G-CSF for CIN Prevention

Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced that it has completed a $6M investment from its long term Private Investor in the form of a Preferred Equity transaction.

Submitted data to U.S. Food and Drug Administration for surrogate endpoint to be used for an Accelerated Approval